Erlotinib in Treating Women Undergoing Surgery For Stage I, Stage II, or Stage III Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: erlotinib hydrochloride|OTHER: immunohistochemistry staining method|OTHER: laboratory biomarker analysis|PROCEDURE: biopsy|PROCEDURE: conventional surgery|PROCEDURE: neoadjuvant therapy
Sponsor: Barbara Ann Karmanos Cancer Institute
Collaborators: National Cancer Institute (NCI)